WHAT: |
Talks will cover:
The promise of how personal genomes can lead to better drug response and disease-risk assessment and how environmental factors such as diet limit that promise.
Innovative approaches of academic-based research that are upending large Pharma’s traditional role as the primary developer of new drugs.
A new collaborative model of drug discovery that is moving away from a single, private company to teams built from academia and the pharmaceutical and biotech industries. |
WHO: |
Garret A. FitzGerald, MD, Robert L. McNeil, Jr., Professor of Translational Medicine and Therapeutics, Chair of Department of Pharmacology, Director of ITMAT and Perelman School of Medicine, University of Pennsylvania (Conference Organizer)
Over 30 thought leaders in translational medicine will participate as speakers and panelists.
Among the Highlights…
Day 1 |
As access to personal genomic information becomes more widespread, is there more to understanding disease risk and response than simply knowing your genome? Hear from speakers with two different perspectives on this issue:
Isaac S. Kohane, MD, PhD, Lawrence J. Henderson Professor of Health Sciences and Technology, Director of the Countway Library of Medicine, Co-Director of the Center for Biomedical Informatics, Harvard Medical School; and Director, i2b2 National Center for Biomedical Computing - Overcoming the Incidentalome for a Responsible Genomic Medicine
Jun Wang, PhD, Executive Director of BGI (formerly known as Beijing Genomics Institute) - Sequencing, Sequencing and Sequencing
Jeremy K. Nicholson, PhD, FRSC, FRCPath, FMedSci, Head of Department of Surgery and Cancer, Imperial College London, UK - Systems Medicine and Patient Journey Phenotyping |
Day 2 |
What happens when genome meets environment? Learn more about the landscape that is so critical for the progression of personalized medicine:
Shelley L. Berger, PhD, Daniel S. Och University Professor, Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania - The Epigenetic Regulation of the Genome |
Day 2 |
How can we fix the current drug development crisis? And what role can academia play? Learn about the traditional and new academic models for drug development from the people who have made them work:
Carl June, MD, Professor of Pathology and Laboratory Medicine, and Program Director for Translational Research in the Abramson Family Cancer Research Institute - Synthetic Biology with Engineered T Cells
Joseph Schlessinger, PhD, William H. Prusoff Professor and Chair of Pharmacology, Yale University School of Medicine - Cell Signaling by Receptor Tyrosine Kinases; from Basic Principles to Cancer Therapy
Peter J. Ratcliffe, MD, FRCP, FMedSci, FRS, Nuffield Professor of Medicine and Head of Department, Nuffield Department of Clinical Medicine, University of Oxford - Drug Target Discovery in Academia |
|